

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

MDA-MB-175-VII

RRID:CVCL_1400

Type: Cell Line

Proper Citation

RRID:CVCL_1400

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1400

Proper Citation: RRID:CVCL_1400

Description: Cell line MDA-MB-175-VII is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Invasive breast carcinoma of no special type

Defining Citation: [PMID:730202](#), [PMID:3518877](#), [PMID:4412247](#), [PMID:10969801](#), [PMID:11044355](#), [PMID:12353263](#), [PMID:12800145](#), [PMID:15677628](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:20070913](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20407441](#), [PMID:22460905](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:28889351](#), [PMID:29610121](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: African American., Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-175-VII

Synonyms: MDA MB 175 VII, MDA-MB-175VII, MDAMB175VII, MDA-MB-175, MDAMB175, MDA-175, MDA175, MD Anderson-Metastatic Breast-175-VII

Cross References: BTO:BTO_0003471, CLO:CLO_0007633, EFO:EFO_0001208, AddexBio:C0006009/4885, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-TABM-157, ATCC:HTB-25, BioSample:SAMN03472690, BioSample:SAMN10987665, cancercellines:CVCL_1400, CCRID:1101HUM-PUMC000349, Cell_Model_Passport:SIDM00633, ChEMBL-Cells:ChEMBL3308404, ChEMBL-Targets:ChEMBL1075497, CLS:305825, Cosmic:687493, Cosmic:809236, Cosmic:871145, Cosmic:894086, Cosmic:897422, Cosmic:904376, Cosmic:908120, Cosmic:934526, Cosmic:997917, Cosmic:1010931, Cosmic:1044227, Cosmic:1046955, Cosmic:1047690, Cosmic:1176646, Cosmic:1287894, Cosmic:1289394, Cosmic:1309001, Cosmic:1434951, Cosmic:1603218, Cosmic:1609470, Cosmic:2165025, Cosmic:2750525, Cosmic-CLP:908120, DepMap:ACH-000759, EGA:EGAS00001000610, GDSC:908120, GEO:GSM115106, GEO:GSM217586, GEO:GSM219930, GEO:GSM320175, GEO:GSM344348, GEO:GSM344398, GEO:GSM350511, GEO:GSM421872, GEO:GSM466359, GEO:GSM783950, GEO:GSM844592, GEO:GSM844593, GEO:GSM847400, GEO:GSM847493, GEO:GSM887294, GEO:GSM888369, GEO:GSM1053731, GEO:GSM1172888, GEO:GSM1172978, GEO:GSM1238134, GEO:GSM1374650, IARC_TP53:21080, IGRhCellID:MDAMB175VII, LiGeA:CCLE_228, LINCS_HMS:50329, LINCS_LDP:LCL-1317, NCBI_Iran:C432, PharmacDB:MDAMB175VII_899_2019, PRIDE:PXD030304, Progenetix:CVCL_1400, PubChem_Cell_line:CVCL_1400, SLKBase:3590, Wikidata:Q54904579

ID: CVCL_1400

Record Creation Time: 20220427T220755+0000

Record Last Update: 20260815T234600+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-175-VII.

No alerts have been found for MDA-MB-175-VII.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Chatterjee E, et al. (2026) Autophagy-lysosomal dependency defines a vulnerable physiological state in drug-tolerant persister cells of triple-negative breast cancer.

Apoptosis : an international journal on programmed cell death, 31(5).

Nagahashi M, et al. (2025) An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia. *Cancer research communications*, 5(6), 981.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. *Cancer cell*, 43(3), 464.

Sonnemann HM, et al. (2024) Placental co-transcriptional activator Vestigial-like 1 (VGLL1) drives tumorigenesis via increasing transcription of proliferation and invasion genes. *Frontiers in oncology*, 14, 1403052.

van Houtum EJ, et al. (2024) Siglec-7 and Siglec-9 expression in primary triple negative and oestrogen receptor positive breast cancer and in vitro signalling. *Clinical & translational immunology*, 13(9), e1524.

Teuber A, et al. (2024) Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA. *Nature communications*, 15(1), 63.

DiPeri TP, et al. (2023) Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(21), 4385.

Schram AM, et al. (2022) Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. *Cancer discovery*, 12(5), 1233.

Amioka A, et al. (2021) Effect of Wnt5a on drug resistance in estrogen receptor-positive breast cancer. *Breast cancer (Tokyo, Japan)*, 28(5), 1062.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.

Odintsov I, et al. (2021) The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(11), 3154.

Liu Y, et al. (2020) Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. *Cell chemical biology*, 27(10), 1229.

Skidmore L, et al. (2020) ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers. *Molecular cancer therapeutics*, 19(9), 1833.

Ding X, et al. (2020) A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity. *EBioMedicine*, 60, 102996.

Chopra SS, et al. (2020) Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. *Cell systems*, 10(1),

66.

Johnstone CN, et al. (2020) FGF13 promotes metastasis of triple-negative breast cancer. *International journal of cancer*, 147(1), 230.

Harris IS, et al. (2019) Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. *Cell metabolism*, 29(5), 1166.

Hirukawa A, et al. (2019) Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy. *Cell reports*, 29(2), 249.

Geuijen CAW, et al. (2018) Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade. *Cancer cell*, 33(5), 922.